Indacaterol

• Description :

  Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder) . Indacaterol can also be used in cardiovascular disease research[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Adrenergic Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cancer; Endocrinology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/indacaterol.html

• Purity :

  99.98

• Solubility :

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=C([C@@H](O)CNC2CC(C=C(CC)C(CC)=C3)=C3C2)C4=C1NC(C=C4)=O

• Molecular Formula :

  C24H28N2O3

• Molecular Weight :

  392.49

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37 (8) :585-91. |[2]Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  β adrenergic receptor

• Citation 01 :

  BioRxiv. 2025 May 29:2025.05.28.656715.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Chromatogr A. 2024 Feb 22:1717:464696.|J Neuroimmunol. 2019 Jul 15:332:37-48.|Pharmaceutics. 2020 Feb 11;12 (2) :145.

• CAS Number :

  [312753-06-3]